Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: Where do we stand?

Leukemia and Lymphoma

Volumn 53, Issue 3, 2012, Pages 362-370

  Van Den Neste, Eric ^a   Letestu, Rémi ^b   Aurran Schleinitz, Thérèse ^c   Ysebaert, Loïc ^d   Feugier, Pierre ^e   Lepretre, Stéphane ^f   Dartigeas, Caroline ^g  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b AVICENNE HOSPITAL   (France)

^c INSTITUT PAOLI CALMETTES   (France)

^d CHU PURPAN   (France)

^e CHU NANCY BRABOIS   (France)

^f CENTRE HENRI BECQUEREL   (France)

^g CHU BRETONNEAU   (France)

Author keywords

Antibody based immunotherapy; Immunotherapy; Lymphoid leukemia

Indexed keywords

ALEMTUZUMAB; BENDAMUSTINE; CLADRIBINE; CYCLOPHOSPHAMIDE; FLUDARABINE; MITOXANTRONE; OLIGONUCLEOTIDE; RITUXIMAB;

ALLELE SPECIFIC OLIGONUCLEOTIDE POLYMERASE CHAIN REACTION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL PROTOCOL; CONSOLIDATION CHEMOTHERAPY; DRUG CHOICE; DRUG EFFICACY; FLOW CYTOMETRY; HUMAN; INFECTION; LEUKEMIA REMISSION; MAINTENANCE CHEMOTHERAPY; MINIMAL RESIDUAL DISEASE; OVERALL SURVIVAL; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

AGAMMAGLOBULINEMIA; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; NEOPLASM, RESIDUAL; NEUTROPENIA; REMISSION INDUCTION; TREATMENT OUTCOME; VIDARABINE;

EID: 84857594522     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.608450     Document Type: Review

References (88)

1. H allek M, Fischer K, Fingerle-Rowson G., et al. Addition of rituximab to fl udarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. Lancet 2010;376:1164-1174.
2. Keating MJ, O ' Brien S, Albitar M., et al. Early results of a chemoimmunotherapy regimen of fl udarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin. Oncol. 2005;23:4079-4088. (Pubitemid 46211313)
3. S ayala HA, Rawstron AC, Hillmen P. Minimal residual disease assessment in chronic lymphocytic leukaemia. Best Pract Res Clin Haematol 2007;20:499-512. (Pubitemid 47250498)
4. W ierda W, O ' Brien S, Wen S., et al. Chemoimmunotherapy with fl udarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin. Oncol. 2005;23:4070-4078. (Pubitemid 46211312)
5. B osch F, Abrisqueta P, Villamor N., et al. Rituximab, fl udarabine, cyclophosphamide, and mitoxantrone: A new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin. Oncol. 2009;27:4578-4584.
6. K ay NE, Geyer SM, Call TG., et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows signifi cant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 2007;109: 405-411. (Pubitemid 46105933)
7. B osch F, Ferrer A, Villamor N., et al. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: High response rate and disease eradication. Clin. Cancer Res. 2008;14: 155-161. (Pubitemid 351377991)
8. M oreno C, Villamor N, Colomer D., et al. Clinical signifi cance of minimal residual disease, as assessed by diff erent techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood 2006;107:4563-4569. (Pubitemid 43801386)
9. L in TS, Donohue KA, Byrd JC., et al. Consolidation therapy with subcutaneous (SC) alemtuzumab after fl udarabine and rituximab (FR) induction therapy improves the complete response (CR) rate in chronic lymphocytic leukemia (CLL) and eradicates minimal residual disease (MRD) but is associated with severe infectious toxicity: Fi nal analysis of CALGB study 10101. Blood 2009;114(Suppl. 1): Abstract 210.
10. B oettcher S, Fischer K, Stilgenbauer S., et al., and on behalf of GCLLSG5. Quantitative MRD assessments predict progression free survival in CLL patients treated with fl udarabine and cyclophosphamide with or without rituximab - a prospective analysis in 471 patients from the randomized GCLLSG CLL8 trial. Blood 2008;112(Suppl. 1): Abstract 326.
11. T am CS, O' B rien S, Wierda W., et al. Long-term results of the fl udarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008;112:975-980.
12. Y sebaert L, Gross E, Kuhlein E., et al. Immune recovery after fl udarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: Implication for maintenance immunotherapy. Leukemia 2010;24:1310-1316.
13. L amanna N, Jurcic JG, Noy A., et al. Sequential therapy with fl udarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces highquality responses: molecular remissions predict for durable complete responses. J Clin. Oncol. 2009;27:491-497.
14. L undin J, Kimby E, Bjorkholm M., et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as fi rstline treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002;100:768-773. (Pubitemid 34832599)
15. H illmen P, Skotnicki AB, Robak T., et al. Alemtuzumab compared with chlorambucil as fi rst-line therapy for chronic lymphocytic leukemia. J. Clin. Oncol. 2007;25:5616-5623.
16. K wok M, Rawstron AC, Varghese A., et al. Minimal residual disease is a predictor for progression-free and overall survival in chronic lymphocytic leukemia (CLL) that is independent of the type or line of therapy. Blood 2009;114(Suppl. 1): Abstract 540.
17. M oreton P, Kennedy B, Lucas G., et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J. Clin. Oncol. 2005;23:2971-2979. (Pubitemid 46224116)
18. H allek M, Cheson BD, Catovsky D., et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446-5456.
19. R awstron AC, Villamor N, Ritgen M., et al. International standardized approach for fl ow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 2007;21:956-964. (Pubitemid 46672072)
20. B ottcher S, Stilgenbauer S, Busch R., et al. Standardized MRD fl ow and ASO IGH RQ-PCR for MRD quantifi cation in CLL patients after rituximab-containing immunochemotherapy: A comparative analysis. Leukemia 2009;23:2007-2017.
21. L etestu R, Lepre t re S, Arnoulet C., et al. CLL2007FMP, a phase III randomized multicentric trial of the French cooperative group on CLL and WM (FCGCLL/MW) and the " Groupe Ouest-Est d ' Etudes des Leuc e mies Aig u es et Autres Maladies du Sang " (GOELAMS): Immunochemotherapy with fl udarabine F, cyclophosphamide (C), and rituximab (R) (FCR) yields a signifi cantly better response than fl udarabine F, cyclophosphamide c and MabCampath (Cam) (FCCam) in previously untreated B-chronic lymphocytic leukemia patients as evaluated by a sensitive 6 color fl ow cytometry MRD. Blood 2010;116(Suppl. 1): Abstract 698.
22. H allek M. State-of-the-art treatment of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2009:440-449.
23. Lepretre S, Aurran T, Mahe B., et al. Immunochemotherapy with fl udarabine F, cyclophosphamide (C), and rituximab (R) (FCR) versus fl udarabine F, cyclophosphamide (C) and MabCampath (Cam)(FCCam) in previously untreated patients (pts) with advanced B-chronic lymphocytic leukemia (B-CLL): Experience on safety and effi cacy within a randomised multicenter phase III trial of the French cooperative group on CLL and WM (FCGCLL/MW) and the " Groupe Ouest-Est d ' Etudes des Leuc e mies Aig u es et Autres Maladies du Sang " (GOELAMS): CLL2007FMP (for fi t medically patients). Blood 2009;114(Suppl. 1): Abstract 538.
24. Wierda WG, O ' Brien S, Ferrajoli A., et al. Combined cyclophosphamide, fl udarabine, alemtuzumab, and rituximab (CFAR), an active frontline regimen for high-risk patients with CLL. Blood 2007;110(Suppl. 1): Abstract 628.
25. T simberidou AM, Tam C, Abruzzo LV., et al. Chemoimmunotherapy may overcome the adverse prognostic signifi cance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia. Cancer 2009;115:373-380.
26. F aderl S, Wierda W, O' B rien S., et al. Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL< 70 years. Leuk Res 2010;34:284-288.
27. A latrash G, Albitar M, O' Brien S., et al. Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fl udarabine, cyclophosphamide and rituximab (FCR). Br J Haematol 2010;148: 386-393.
28. R obak T, Blonski JZ, Gora-Tybor J., et al. Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: Report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood 2006;108:473-479. (Pubitemid 44061344)
29. Fischer K, Cramer P, Stilgenbauer S., et al., and the German CLL Study Group (GCLLSG). Bendamustine combined with rituximab (BR) in fi rst-line therapy of advanced CLL: A multicenter phase II trial of the German CLL Study Group (GCLLSG). Blood 2009;114(Suppl. 1): Abstract 205.
30. M ontillo M, Tedeschi A, Miqueleiz S., et al. Alemtuzumab as consolidation after a response to fl udarabine is eff ective in purging residual disease in patients with chronic lymphocytic leukemia. J. Clin. Oncol. 2006;24:2337-2342. (Pubitemid 46630666)
31. Lin TS, Donohue KA, Byrd JC., et al. Consolidation therapy with subcutaneous alemtuzumab after fl udarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: Fi nal analysis of CALGB 10101. J. Clin. Oncol. 2010;28:4500-4506.
32. Wierda WG, Kipps TJ, Keating MJ., et al. Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia. Cancer 2011;117:116-124.
33. O ' Brien SM, Kantarjian HM, Thomas DA., et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 2003;98:2657-2663. (Pubitemid 37509530)
34. S chweighofer CD, Ritgen M, Eichhorst BF., et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in fi rst remission: Long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). Br J Haematol 2009;144:95-98.
35. W endtner CM, Ritgen M, Schweighofer CD., et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in fi rst remission-experience on safety and effi cacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 2004;18:1093-1101. (Pubitemid 38786968)
36. Dyer MJ, Kelsey SM, Mackay HJ., et al. In vivo " purging " of residual disease in CLL with Campath-1H. Br. J. Haematol. 1997;97:669-672. (Pubitemid 27261639)
37. Delmer A, Lepretre S, Cazin B., et al. Consolidation therapy with subcutaneous alemtuzumab following induction treatment with oral FC (fl udarabine and cyclophosphamide) in previously untreated patients aged 65-70 years with advanced stage chronic lymphocytic leukemia (CLL): A phase II trial of the FCGCLL/MW. Blood 2006;108(Suppl. 1): Abstract 2831.
38. Hainsworth JD, Vazquez ER, Spigel DR., et al. Combination therapy with fl udarabine and rituximab followed by alemtuzumab in the fi rst-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase 2 trial of the Minnie Pearl Cancer Research Network. Cancer 2008;112:1288-1295. (Pubitemid 351429744)
39. K aufman MS, Caramanica A, Janson D., et al. Alemtuzumab maintenance may safely prolong chemotherapy-free intervals in chronic lymphocytic leukemia. Med. Oncol. 2100;28:532-538.
40. Th ieblemont C, Bouafi a F, Hornez E., et al. Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL). Leuk Lymphoma 2004;45:711-714. (Pubitemid 38256030)
41. S tilgenbauer S, Cymbalista F, Leblond V., et al. Subcutaneous alemtuzumab combined with oral dexamethasone, followed by alemtuzumab maintenance or allo-SCT in CLL with 17p- or refractory to fl udarabine - interim analysis of the CLL2O trial of the GCLLSG and FCGCLL/MW. Blood 2010;116(Suppl. 1): Abstract 920.
42. O ' Brien SM, Kantarjian H, Thomas DA., et al. Rituximab doseescalation trial in chronic lymphocytic leukemia. J. Clin. Oncol. 2001;19:2165-2170. (Pubitemid 32366970)
43. D el Poeta G, Del Principe MI, Buccisano F., et al. Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. Cancer 2008;112:119-128.
44. G arcia-Marco JA, Lopez-Jimenez J, Ferrer S., et al. Rituximab maintenance treatment after combined fl udarabine, cyclophosphamide and rituximab in previously untreated patients with progressive B-cell chronic lymphocytic leukemia (CLL): Interim analysis of an ongoing phase II multicenter trial on behalf of the Spanish CLL Study Group (GELLC). Blood 2010;116(Suppl. 1): Abstract 2448.
45. E gle A, Weiss L, Melchardt T., et al. Final analysis of induction treatment with fl udarabine, cyclophosphamide plus rituximab (FCR) followed by fl udarabine plus rituximab (FR) and remission maintenance therapy with rituximab in previously untreated B-chronic lymphocytic eukemia (B-CLL): The Chairos AGMT CLL4/Roche ML18434 study. Blood 2010;116(Suppl. 1): Abstract 1380.
46. B yrd JC, Peterson BL, Morrison VA., et al. Randomized phase 2 study of fl udarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003;101:6-14. (Pubitemid 36025880)
47. Scaramucci L, Niscola P, Buff olino S., et al. Repeated rituximab maintenance courses in fl udarabine-failed young patients with chronic lymphocytic leukaemia responding to FAND chemotherapy. Hematol J 2004;5:186-187. (Pubitemid 38519270)
48. F oon KA, Boyiadzis M, Land SR., et al. Chemoimmunotherapy with low-dose fl udarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J. Clin. Oncol. 2009;27:498-503.
49. H ainsworth JD, Litchy S, Barton JH., et al. Single-agent rituximab as fi rst-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase II trial of the Minnie Pearl Cancer Research Network. J. Clin. Oncol. 2003;21:1746-1751. (Pubitemid 46638587)
50. S rock S, Schriever F, Neubauer A., et al. Long-term treatment with rituximab is feasible in selected patients with B-CLL: Responseadjusted low-dose maintenance treatment with rituximab in patients with relapsed B-CLL, who achieved a partial or minimal response to prior rituximab therapy. Leuk Lymphoma 2007;48:905-911. (Pubitemid 47161562)
51. H ainsworth JD. First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkins lymphoma. Semin Oncol 2003;30:9-15. (Pubitemid 36337347)
52. F oa R, Ciolli S, Di Raimondo F., et al. A phase II study of chlorambucil plus rituximab followed by maintenance versus observation in elderly patients with previously untreated chronic lymphocytic leukemia: Results of the fi rst interim analysis. Blood 2010;116(Suppl. 1): Abstract 2462.
53. F errajoli A. Treatment of younger patients with chronic lymphocytic leukemia. Hematology Am. Soc. Hematol. Educ. Program. 2010:82-89.
54. M occia A, Ghielmini M. Monoclonal antibodies for the treatment of hematologic malignancies: Schedule and maintenance therapy. Semin Hematol 2008;45:75-84. (Pubitemid 351434411)
55. F ischer K, Schweighofer C, Ritgen M., et al. Dose escalation study to evaluate dose limiting toxicity (DLT), maximum tolerated dose (MTD) and safety of alemtuzumab for consolidation therapy in patients with chronic lymphoycytic leukemia: Phase I/II trial of the German CLL Study Group (GCLLSG). Blood 2007;110(Suppl. 1): Abstract 2053.
56. M aung ZT, Wood AC, Jackson GH., et al. Transfusion-associated graft-versus-host disease in fl udarabine-treated B-chronic lymphocytic leukaemia. Br. J. Haematol. 1994;88:649-652. (Pubitemid 24345123)
57. K luin-Nelemans HC, Coenen JL, Boers JE., et al. EBV-positive immunodefi ciency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. Blood 2008;112:1039-1041.
58. W olach O, Bairey O, Lahav M. Late-onset neutropenia after rituximab treatment: Case series and comprehensive review of the literature. Medicine (Baltimore) 2010;89:308-318.
59. Vidal L, Gafter-Gvili A, Leibovici L., et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: Systematic review and meta-analysis of randomized trials. J. Natl. Cancer Inst. 2009;101:248-255.
60. v an Oers MH, Van Glabbeke M, Giurgea L., et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkins lymphoma: Long-term outcome of the EORTC 20981 phase III randomized intergroup study. J. Clin. Oncol. 2010;28:2853-2858.
61. Salles G, Seymour JF, Off ner F., et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial. Lancet 2011;377:42-51.
62. Casulo C, Maragulia J, Zelenetz A. Hypogammaglobulinemia in pts receiving rituximab immunotherapy and the impact of rituximab maintenance. J. Clin. Oncol. 2010;28(15 Suppl.): Abstract 8088.
63. Gea-Banacloche JC. Rituximab-associated infections. Semin Hematol 2010;47:187-198.
64. D ' S ouza A, Wilson J, Mukherjee S., et al. Progressive multifocal leukoencephalopathy in chronic lymphocytic leukemia: A report of three cases and review of the literature. Clin Lymphoma Myeloma Leuk 2010;10:E1-E9.
65. Y agci M, Ozkurt ZN, Yegin ZA., et al. Hepatitus B virus reactivation in HBV-DNA negative and positive patients with hematological malignancies. Hematology 2010;15:240-244.
66. Bitzan M, Anselmo M, Carpineta L. Rituximab (B-cell depleting antibody) associated lung injury (RALI): A pediatric case and systematic review of the literature. Pediatr Pulmonol 2009;44:922-934.
67. Dayde D, Ternant D, Ohresser M., et al. Tumor burden infl uences exposure and response to rituximab: Pharmacokineticpharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. Blood 2009;113:3765-3772.
68. Li J, Zhi J, Wenger M., et al. Higher doses of rituximab may be required for patients with CLL as compared to NHL based on population pharmacokinetic (PK) modeling. Blood 2009;114(Suppl. 1): Abstract 1742.
69. Manshouri T, Do KA, Wang X., et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic signifi cance. Blood 2003;101:2507-2513. (Pubitemid 36857605)
70. Beum PV, Kennedy AD, Taylor RP. Th ree new assays for rituximab based on its immunological activity or antigenic properties: Analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas. J. Immunol. Methods 2004;289:97-109. (Pubitemid 38900908)
71. B eers SA, French RR, Chan HT., et al. Antigenic modulation limits the effi cacy of anti-CD20 antibodies: Implications for antibodyselection. Blood 2010;115:5191-5201.
72. T aylor RP, Lindorfer MA. Antigenic modulation and rituximab resistance. Semin Hematol 2010;47:124-132.
73. R itz J, Schlossman SF. Utilization of monoclonal antibodies in the treatment of leukemia and lymphoma. Blood 1982;59:1-11. (Pubitemid 12162338)
74. Beum PV, Kennedy AD, Williams ME., et al. Th e shaving reaction: Rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J. Immunol. 2006;176:2600-2609. (Pubitemid 43201712)
75. Taylor R, Beum P, Lindorfer M., et al. Examination of the relative rates of rituximab-mediated loss of CD20 from B cells via trogocytosis versus internalization. Implications for rituximab therapy of CLL. Blood 2010;116(Suppl. 1): Abstract 2404.
76. Kennedy AD, Beum PV, Solga MD., et al. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J. Immunol. 2004;172:3280-3288. (Pubitemid 38263720)
77. D ' Auria F, Guariglia R, Villani O., et al. Modulation of CD20 antigen expression after rituximab treatment: A retrospective study in patients with chronic lymphocytic leukemia. Clin Th er 2010;32:1911-1916.
78. Williams ME, Densmore JJ, Pawluczkowycz AW., et al. Th riceweekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J. Immunol. 2006;177:7435-7443. (Pubitemid 44715114)
79. Byrd JC, Murphy T, Howard RS., et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J. Clin. Oncol. 2001;19:2153-2164. (Pubitemid 32366969)
80. A ue G, Lindorfer MA, Beum PV., et al. Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia. Haematologica 2010;95:329-332.
81. M ankai A, Buhe V, Hammadi M., et al. Improvement of rituximab effi ciency in chronic lymphocytic leukemia by CpG-mediated upregulation of CD20 expression independently of PU.1. Ann NY Acad Sci 2009;1173:721-728.
82. S ivaraman S, Deshpande CG, Ranganathan R., et al. Tumor necrosis factor modulates CD 20 expression on cells from chronic lymphocytic leukemia: A new role for TNF alpha? Microsc Res Tech 2000;50:251-257. (Pubitemid 30610102)
83. Klepfi sh A, Gilles L, Ioannis K., et al. Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: Complement/rituximab interactions & clinical results in refractory CLL. Ann NY Acad Sci 2009;1173:865-873.
84. . Incorporating the use of GM-CSF in the treatment of chronic lymphocytic leukemia. Leuk Lymphoma 2009;50:514-516.
85. P oire X, Kline J, Grinblatt D., et al. Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. Leuk Lymphoma 2010;51:1241-1250.
86. Wu L, Adams M, Carter T., et al. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20- tumor cells. Clin. Cancer Res. 2008;14:4650-4657.
87. Andersen NS, Pedersen LB, Laurell A., et al. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. J. Clin. Oncol. 2009;27:4365-4370.
88. O'Brien S, Kay NE. Maintenance therapy for B-chronic lymphocytic leukemia. Clin Adv Hematol Oncol 2011;9:22-31